Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESOLVE-SEX
NCT05597098Phase 1Active, not recruiting
- Sponsor
- Queen Mary University of London
- Start
- Dec 2022
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 1, open-label trial of cantharidin (2 arms), sponsored by Queen Mary University of London. Primary endpoints: Presence of blister at 72 hours, Blister volume at 72 hours and 1 more. Started Dec 2022; status: active, not recruiting.
02
Drugs
cantharidin
Beyond the preview
Go deeper on NCT05597098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05597098.